Chr. Hansen’s 2’-FL HMO approved for infant formula in Australia and New Zealand

Chr. Hansen’s 2’-FL HMO approved for infant formula in Australia and New Zealand
Press Release | Jun 14. 2022 06:57 GMT

Enabling customers to bring more health benefits to bottle-fed babies

Food Standards Australia New Zealand, FSANZ, has approved Chr. Hansen's 2'-FL human milk oligosaccharide for infant formula in Australia and New Zealand. 2'-FL HMO is the most abundant and most studied human oligosaccharide in breast milk, used in infant formula around the world since 2016.

“As one of the leading suppliers of HMOs, we are pleased to have our 2'-FL HMO ingredient officially approved by national authorities in Australia and New Zealand. In these attractive markets we can now support our customers in supplying leading infant formula products that are closer to breast milk,” says Jesper Sig Mathiasen, senior vice president, Chr. Hansen HMO.

Widely approved
HMO 2'-FL is not only the most studied HMO; it is also the most abundant, making up 20-30% of the total HMO composition in breast milk. It was discovered in 1954 and was the first HMO to be commercially produced and recognized as safe by the North American and European food safety authorities, FDA and EFSA. Thus, HMOs are approved as an ingredient for infant formula in many global markets, now including Chr. Hansen 2'-FL for Australia and New Zealand.

“Breastfeeding is the best way to ensure infant health and recommended by WHO. At Chr. Hansen, we further aim to support the healthy development of infants that cannot be breastfed by providing HMOs as an ingredient for infant formula,” explains Dr. Katja Parschat, head of Research & Development at Chr. Hansen HMO.

“The latest research shows that HMOs contribute to health benefits, such as supporting the immune system and healthy brain development. Also, HMOs are indicated to support gut maturation and resilience, as well as promotion of a balanced gut microbiome. We are happy to be able to offer our solutions to customers in Australia and New Zealand now,” Dr. Parschat concludes.

Chr. Hansen's product offering
Next to 2'-FL, Chr. Hansen also offers a 5 HMO Mix that is composed to reflect the natural concentrations of HMOs in breast milk. It contains HMOs of each structural group (fucosylated HMOs, neutral, non-fucosylated and sialylated HMOs) by including 2'-FL, 3'FL, LNT, 6’-SL and 3’-SL HMOs.



Breastfeeding is best. Chr. Hansen supports the World Health Organization (WHO) recommendation of breastfeeding exclusively for the first six months, followed by continued breastfeeding together with complementary foods.


Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Share this with: